BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27538768)

  • 1. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    J Clin Pharm Ther; 2012 Apr; 37(2):217-20. PubMed ID: 21517926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Optimization of Immunosuppression and the Prevention of Fungal Infection in Autoimmune Diseases].
    Mino Y
    Yakugaku Zasshi; 2015; 135(10):1123-7. PubMed ID: 26423867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.
    Mino Y; Naito T; Otsuka A; Ozono S; Kagawa Y; Kawakami J
    Clin Chim Acta; 2009 Nov; 409(1-2):56-61. PubMed ID: 19723513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic monitoring of mycophenolate mofetil.
    Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
    Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
    Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
    Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
    Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L
    J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
    Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
    J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
    Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
    Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic variability of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in remission maintenance phase.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    Biol Pharm Bull; 2011; 34(5):755-9. PubMed ID: 21532168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
    Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
    Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.
    Sagcal-Gironella AC; Fukuda T; Wiers K; Cox S; Nelson S; Dina B; Sherwin CM; Klein-Gitelman MS; Vinks AA; Brunner HI
    Semin Arthritis Rheum; 2011 Feb; 40(4):307-13. PubMed ID: 20655577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
    Rath T; Küpper M
    Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
    Jonsson CA; Svensson L; Carlsten H
    Clin Exp Immunol; 1999 Jun; 116(3):534-41. PubMed ID: 10361247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study.
    Roland M; Barbet C; Paintaud G; Magdelaine-Beuzelin C; Diot E; Halimi JM; Lebranchu Y; Nivet H; Büchler M
    Lupus; 2009 Apr; 18(5):441-7. PubMed ID: 19318398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients.
    Mandla R; Line PD; Midtvedt K; Bergan S
    Ther Drug Monit; 2003 Jun; 25(3):407-14. PubMed ID: 12766573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of inosine monophosphate dehydrogenase activity by the plasma of heart transplant recipients receiving mycophenolate mofetil.
    Griesmacher A; Weigel G; Seebacher G; Mallinger R; Laufer G; Müller MM
    Adv Exp Med Biol; 1998; 431():537-41. PubMed ID: 9598124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.